Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Decreases By 90.0%

GeoVax Labs Inc. (NASDAQ:GOVX) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 151,504 shares, a decline of 90.0% from the December 31st total of 1,514,630 shares. Approximately 12.7% of the shares of the company are sold short. Based on an average daily trading volume, of 211,349 shares, the short-interest ratio is presently 0.7 days. Based on an average daily trading volume, of 211,349 shares, the short-interest ratio is presently 0.7 days. Approximately 12.7% of the shares of the company are sold short.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Wall Street Zen lowered GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. D. Boral Capital reiterated a “buy” rating on shares of GeoVax Labs in a report on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $187.50.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors have recently made changes to their positions in the company. Sabby Management LLC bought a new stake in shares of GeoVax Labs during the third quarter worth about $313,000. Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter valued at $253,000. Hudson Bay Capital Management LP purchased a new stake in GeoVax Labs during the 3rd quarter worth about $47,000. Finally, Jane Street Group LLC bought a new position in shares of GeoVax Labs in the first quarter worth $27,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock remained flat at $2.84 during trading on Wednesday. The company had a trading volume of 100,013 shares, compared to its average volume of 222,416. The firm has a market capitalization of $3.41 million, a PE ratio of -0.08 and a beta of 3.67. The stock has a 50 day moving average of $6.27 and a 200-day moving average of $12.82. GeoVax Labs has a fifty-two week low of $2.61 and a fifty-two week high of $51.75.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) earnings per share for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. Sell-side analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.